Bastide Le Confort Medical


Steady growth and active M&As should continue

12/05/22 -"Bastide’s Q3 revenue continued to be affected by last year’s pandemic-led unfavourable comparable base but the anomalies should not persist for long. The group has maintained its FY guidance ..."

Pages
50
Language
English
Published on
12/05/22
You may also be interested by these reports :
25/05/22
Elekta ended FY22 on a healthy note, with Q4 results exceeding street expectations. Sales growth was witnessed in both segments. Importantly, order ...

19/05/22
Given the steady recovery witnessed across the non-Covid testing space, our estimates reset higher. Besides that, we have removed the 10% discount on ...

19/05/22
We reiterate our pessimistic stance on Orpea. On top of those in France, government investigations were recently launched in other European countries ...

18/05/22
Sonova reported healthy H2 sales, although profitability was a miss vs. market expectations. Top-line growth was witnessed across segments, with ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO